Medpace Holdings Past Earnings Performance

Past criteria checks 6/6

Medpace Holdings has been growing earnings at an average annual rate of 25%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 20.4% per year. Medpace Holdings's return on equity is 41.5%, and it has net margins of 17.7%.

Key information

25.0%

Earnings growth rate

28.8%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate20.4%
Return on equity41.5%
Net Margin17.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Medpace Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:01P Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,0713661770
30 Jun 242,0303401690
31 Mar 241,9633121670
31 Dec 231,8862831610
30 Sep 231,7822731520
30 Jun 231,6732681460
31 Mar 231,5632571400
31 Dec 221,4602451310
30 Sep 221,3742271260
30 Jun 221,2862091180
31 Mar 221,2131991120
31 Dec 211,1421811080
30 Sep 211,0941821030
30 Jun 211,028175980
31 Mar 21955159930
31 Dec 20926145920
30 Sep 20896124910
30 Jun 20882107970
31 Mar 20891110990
31 Dec 19861100950
30 Sep 1982393950
30 Jun 1978688840
31 Mar 1974278810
31 Dec 1870573760
30 Sep 1861261720
30 Jun 1853152700
31 Mar 1845645640
31 Dec 1738639630
30 Sep 1738228630
30 Jun 1737923630
31 Mar 1737718630
31 Dec 1637113620
30 Sep 163615650
30 Jun 163480600
31 Mar 16332-5570
31 Dec 15320-9540
31 Dec 14290-16400
31 Dec 1324425350

Quality Earnings: 01P has high quality earnings.

Growing Profit Margin: 01P's current net profit margins (17.7%) are higher than last year (15.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 01P's earnings have grown significantly by 25% per year over the past 5 years.

Accelerating Growth: 01P's earnings growth over the past year (33.9%) exceeds its 5-year average (25% per year).

Earnings vs Industry: 01P earnings growth over the past year (33.9%) exceeded the Life Sciences industry -1.4%.


Return on Equity

High ROE: 01P's Return on Equity (41.5%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 04:37
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medpace Holdings, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Ishan MajumdarBaptista Research
Erin Wilson WrightCredit Suisse